Cardiff Oncology, Inc.CRDFNASDAQ
Loading
Year-over-year earnings per share growth rate
3Y CAGR
+88.6%/yr
vs -15.8%/yr prior
Acceleration
+104.4pp
Accelerating
Percentile
P87
Within normal range
vs 3Y Ago
6.7x
Strong expansion
Streak
2 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 35.29% |
| Q3 2025 | 19.05% |
| Q2 2025 | -5.00% |
| Q1 2025 | 20.00% |
| Q4 2024 | 0.00% |
| Q3 2024 | 3.85% |
| Q2 2024 | -18.18% |
| Q1 2024 | -4.76% |
| Q4 2023 | 4.55% |
| Q3 2023 | 12.00% |
| Q2 2023 | -8.70% |
| Q1 2023 | -27.78% |
| Q4 2022 | 5.26% |
| Q3 2022 | 20.83% |
| Q2 2022 | 4.00% |
| Q1 2022 | -8.70% |
| Q4 2021 | -35.29% |
| Q3 2021 | 0.00% |
| Q2 2021 | -21.43% |
| Q1 2021 | 50.00% |
| Q4 2020 | -47.37% |
| Q3 2020 | 32.14% |
| Q2 2020 | 31.71% |
| Q1 2020 | 19.61% |
| Q4 2019 | 26.09% |
| Q3 2019 | 9.21% |
| Q2 2019 | 20.83% |
| Q1 2019 | 11.93% |
| Q4 2018 | 0.91% |
| Q3 2018 | 63.70% |
| Q2 2018 | 51.29% |
| Q1 2018 | -34.63% |
| Q4 2017 | 45.45% |
| Q3 2017 | 54.73% |
| Q2 2017 | 19.53% |
| Q1 2017 | -15.73% |
| Q4 2016 | 17.90% |
| Q3 2016 | 0.20% |
| Q2 2016 | 1.25% |
| Q1 2016 | -38.87% |